Pharmacotherapy for Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia: Past, Present, and Future
Candice D. Fike, Judy L. AschnerUniversity of Utah Health. Joseph M. Sanzari Children’s Hospital at Hackensack University.United States PharmaceuticalsPharmaceuticals 2023; 16: DOI: 10.3390/ph16040503 AbstractApproximately 8-42% of premature infants with chronic lung disease of prematurity, bronchopulmonary dysplasia (BPD), develop pulmonary hypertension (PH). Infants with BPD-PH carry alarmingly high mortality rates of up to 47%. Effective PH-targeted pharmacotherapies […]
